Skip to main content
letter
. 2022 May 25;41(8):2601–2604. doi: 10.1007/s10067-022-06216-w

Table 1.

“Patients’ and disease’s characteristics and outcomes”: characteristics of enclosed patients for both disease and COVID-19 and results of pulmonary function tests before SARS-CoV2 infection (no more than 3 months) and 6 months after the healing from COVID-19

Patients’ disease characteristics at COVID-19 infection COVID-19 characteristics
Patient Sex ARS Anti-Ro52 Age (years) Disease duration (months) ASSD triad Lung pattern Ongoing treatment COVID-19 length (days) Hospital admission Dyspnoea Pneumonia
1 m Jo1 Negative 68 22 AMI NSIP Cys + MTX + PDN (5 mg/day) + O2 (intermittent) 16 yes yes yes
2 f Jo1 Negative 26 103 AMI UIP Cys 24 No No No
3 f Jo1 Negative 50 141 MI NSIP + OP Aza + HCQ + PDN (6.25 mg/day) 42 No No No
4 f Jo1 Positive 38 91 AMI NSIP Cys 10 No No No
5 f Jo1 Negative 49 41 AMI NSIP Cys + MTX + HCQ + PDN (5 mg/day) 6 Yes Yes Yes
6 f PL7 Positive 51 19 MI NSIP Cys + PDN (7.5 mg/day) + O2 (intermittent) 46 No No No
7 m Jo1 Negative 44 72 AMI OP Cys + Aza + PDN (7.5 mg/day) 16 No No No
8 f PL12 Negative 65 68 AM – MTX 28 No No No
9 m Jo1 Negative 60 58 AMI NSIP MTX 50 Yes Yes Yes
10 f PL7 Negative 51 12 MI NSIP MTX + PDN (5 mg/day) + O2 therapy (intermittent) 14 Yes Yes Yes
11 f Jo1 Negative 85 63 AMI NSIP Cys + PDN (7.5 mg/day) + O2 (intermittent) 24 Yes Yes Yes
12 f PL7 Positive 63 16 I NSIP – 9 Yes Yes No
COVID-19 characteristics ASSD manifestations outcome
Minimum SaO2 T max (°C) Other symptoms Covid-19 treatment Disease flares (months after COVID-19) New clinical findings (months after COVID-19) Basal FVC 6 months FVC Basal DLCO 6 months DLCO
90 38.5 - Desa + Rem + LWMH + O2 Lung (2), joints (4) Raynaud's phenomenon (1), pulmonary hypertension (6), myocarditis (6) 87 84 p=0.128* 59 40 p=0.684*
97 37.5 Anosmia, diarrhea, headache – No No 62 58 54 44
98 36.4 Anosmia – No No 106 99 57 78
97 37.9 Anosmia, headache – No No 80 84 76 75
92 38.5 Diarrhea Desa + LWMH No No 83 94 59 66
97 37.7 Anosmia, ageusia – No No 38 46 32 33
98 36.5 Anosmia – No No 78 77 45 47
98 37.5 Anosmia, ageusia, headache – No No 136 102 95 101
93 38 Headache – No No 94 85 95.6 128
89 38 Diarrhea, Headache PDN No No 82 82 45 42
90 38 Anosmia Desa + LWMH + O2 No Diaphragm impairment (6) 69 42 42 35
95 38 Anosmia, ageusia – No no 114 100 51 45

ASSD antisynthetase syndrome, ARS anti-aminoacyl tRNA synthetase antibodies, T max (°C) maximum body temperature in Celsius degree, m male, f female, PL7 anti-threonyl-tRNA synthetase antibodies, PL12 anti-alanyl-tRNA synthetase antibodies, Jo1 anti-histidyl-tRNA synthetase antibodies, AMI arthritis, myositis, interstitial lung disease, MI myositis, interstitial lung disease, AM arthritis, myositis, I interstitial lung disease, NSIP non-specific interstitial pneumonia, UIP usual interstitial pneumonia, OP organizing pneumonia, Cys Cyclosporine, MTX methotrexate, Aza Azathioprine, PDN prednisone, HCQ hydroxychloroquine, FVC forced vital capacity, DLCO diffusing capacity for carbon monoxide, SaO2 peripheral oxygen saturation, O2 oxygen, Desa dexamethasone, Rem remdesivir, LWMH low weight molecular heparin

*Statistical analysis by paired sample t-test